Showing 6,201 - 6,220 results of 27,187 for search '(( 5 ((teer decrease) OR (nn decrease)) ) OR ( 50 ((a decrease) OR (mean decrease)) ))', query time: 0.77s Refine Results
  1. 6201
  2. 6202
  3. 6203
  4. 6204
  5. 6205
  6. 6206
  7. 6207
  8. 6208
  9. 6209
  10. 6210
  11. 6211

    Data_Sheet_1_The Salvinorin Analogue, Ethoxymethyl Ether Salvinorin B, Promotes Remyelination in Preclinical Models of Multiple Sclerosis.PDF by Kelly F. Paton (3934061)

    Published 2021
    “…In the experimental autoimmune encephalomyelitis model, we found that EOM SalB (0.1–0.3 mg/kg) effectively decreased disease severity in a KOR-dependent manner and led to a greater number of animals in recovery compared to U50,488 treatment. …”
  12. 6212
  13. 6213

    Unusual clinical phenotype of Stargardt disease by Pedro Molina-Solana (12683949)

    Published 2022
    “…Pattern electroretinogram demonstrated bilateral decrease of p50 values. Genetic testing identified two heterozygous missense mutations, c.428C>T, p.…”
  14. 6214

    Transcriptome-microRNA analysis of <i>Sarcoptes scabiei</i> and host immune response by Ran He (207626)

    Published 2017
    “…<div><p>Scabies is a parasitic disease, caused by the mite <i>Sarcoptes scabiei</i>, and is considered one of the top 50 epidemic diseases and one the most common human skin disease, worldwide. …”
  15. 6215
  16. 6216

    Protective Effects of Triphala on Dermal Fibroblasts and Human Keratinocytes by Sandeep R. Varma (843403)

    Published 2016
    “…TE also exhibited anti-tyrosinase and melanin inhibition properties in a dose-dependent manner. TE increased the mRNA expression of collagen-I, elastin, superoxide dismutase (SOD-2), aquaporin-3 (AQP-3), filaggrin, involucrin, transglutaminase in HDF or HaCaT cells, and decreased the mRNA levels of tyrosinase in B16F10 cells. …”
  17. 6217
  18. 6218
  19. 6219
  20. 6220

    Risk of Incident Diabetes Related to Lipoprotein(a), LDL Cholesterol, and Their Changes with Alirocumab: Post-Hoc Analyses of the ODYSSEY OUTCOMES Randomized Trial by Gregory G. Schwartz (20599125)

    Published 2025
    “…<a href="" target="_blank">OR for NOD for 25% and 50% lipoprotein(a) reductions were 1.12 (95% CI 1.01</a>-1.23) and 1.24 (1.02-1.52). …”